![Man ultramarathon runner in the mountains he trains at sunset](https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0B4B1380-42EB-4FD5-9D7E2DBC603E79F8/webimage-C4875379-1478-416F-B03DF68FE3D8DBB5.png)
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Pharmacol. , 25 March 2019
Sec. Renal Pharmacology
Volume 10 - 2019 | https://doi.org/10.3389/fphar.2019.00224
This article is part of the Research Topic Innovative Biologics and Drugs to Target Renal Inflammation View all 10 articles
A retraction of this article was approved in:
Retraction: CXCL6 promotes renal interstitial fibrosis in diabetic nephropathy by activating JAK/STAT3 signaling pathway
Citation: Sun M-Y, Wang S-J, Li X-Q, Shen Y-L, Lu J-R, Tian X-H, Rahman K, Zhang L-J, Nian H and Zhang H (2019) CXCL6 Promotes Renal Interstitial Fibrosis in Diabetic Nephropathy by Activating JAK/STAT3 Signaling Pathway. Front. Pharmacol. 10:224. doi: 10.3389/fphar.2019.00224
Received: 25 September 2018; Accepted: 22 February 2019;
Published: 25 March 2019; Retracted: 05 December 2024.
Edited by:
Matthew Griffin, National University of Ireland Galway, IrelandReviewed by:
Peter Jon Nelson, Ludwig Maximilian University of Munich, GermanyDisclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.